Sign up to save your podcasts
Or
Share The $470 Billion Drug War: Novo vs. Lilly 🧠Tech Takedown
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
The $470 Billion Drug War: Novo vs. Lilly 🧠Tech Takedown
The race for the first trillion-dollar pharmaceutical franchise is on. đź’Š We investigate the cutthroat battle between Novo Nordisk (Ozempic/Wegovy) and Eli Lilly (Zepbound/Mounjaro) for dominance in the GLP-1 weight loss market, which is projected to hit $470 billion in revenue by 2030.
1. The Innovation Gap: We break down why Novo is on the defensive. While Novo relies on Semaglutide (a mono-agonist), Eli Lilly has leaped ahead with Tirzepatide, a dual-agonist that hits multiple hormonal pathways for superior weight loss. We analyze Lilly’s next-gen Retatrutide (a triple-agonist), which is showing "bariatric surgery-level" results of 24% weight loss, threatening to make current drugs obsolete.
2. The Patent Fortress: How do you protect a gold mine? We expose Novo’s aggressive "Patent Thicket" strategy. With their main patent expiring in 2031, Novo has filed hundreds of additional patents on delivery devices and specific uses to block generics until 2042, creating a legal fortress to protect an estimated $166 billion in future revenue.
3. The Pill Revolution: The next battleground isn't an injection; it's a pill. 🍬 We discuss the race for an oral GLP-1. Lilly’s Orforglipron offers a convenient daily pill with no fasting requirements, projected to generate $14 billion by 2031, while Novo’s competing pill struggles with strict fasting rules, creating a potential $12 billion revenue gap.
View all episodes
By MorgrainThe race for the first trillion-dollar pharmaceutical franchise is on. đź’Š We investigate the cutthroat battle between Novo Nordisk (Ozempic/Wegovy) and Eli Lilly (Zepbound/Mounjaro) for dominance in the GLP-1 weight loss market, which is projected to hit $470 billion in revenue by 2030.
1. The Innovation Gap: We break down why Novo is on the defensive. While Novo relies on Semaglutide (a mono-agonist), Eli Lilly has leaped ahead with Tirzepatide, a dual-agonist that hits multiple hormonal pathways for superior weight loss. We analyze Lilly’s next-gen Retatrutide (a triple-agonist), which is showing "bariatric surgery-level" results of 24% weight loss, threatening to make current drugs obsolete.
2. The Patent Fortress: How do you protect a gold mine? We expose Novo’s aggressive "Patent Thicket" strategy. With their main patent expiring in 2031, Novo has filed hundreds of additional patents on delivery devices and specific uses to block generics until 2042, creating a legal fortress to protect an estimated $166 billion in future revenue.
3. The Pill Revolution: The next battleground isn't an injection; it's a pill. 🍬 We discuss the race for an oral GLP-1. Lilly’s Orforglipron offers a convenient daily pill with no fasting requirements, projected to generate $14 billion by 2031, while Novo’s competing pill struggles with strict fasting rules, creating a potential $12 billion revenue gap.